AI-guided treatment decisions
Developing AI to predict treatment benefit from routine pathology.
Phenotix is developing AI-based decision support designed to transform standard digitized pathology samples and clinical data into rapid insights for breast cancer treatment decisions.
Product in development
Built on RCT-based academic research
Academic study in The Lancet Oncology
ROUTINE H&E
Digital pathology sample
In development
AI SIGNAL
Treatment-benefit research
PathologyAI analysisClinical insight
What Phenotix is developing
Aiming for faster, more accessible and more precise treatment decisions.
Phenotix Breast is being developed to help clinicians estimate who is likely to benefit from chemotherapy and who may avoid unnecessary treatment—using routine pathology and clinical data.
More precise decisions
Aims to predict treatment benefit—not only prognosis—and support more individualized chemotherapy decisions.
Expanded access
Uses routine pathology and clinical data, making advanced treatment guidance available where genomic testing is limited.
Faster answers
Designed to return results in under three days using samples already collected during routine care.
Academic foundation
Published research informing product development.
Phenotix Breast is being developed on the basis of academic research conducted at the Technion. In that work, a research model was evaluated using data from a randomized trial and six independent international cohorts. The product undergoes dedicated development and validation.
ACADEMIC PEER-REVIEWED PUBLICATION
2026
The Lancet Oncology
Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.
Read the publication Academic model evaluated using data from a randomized trial
13,781 patients
Included in the published academic study.
International evaluation
Academic cohorts from Israel, the United States and Australia.
Treatment-benefit research
The academic study investigated prediction of benefit beyond prognosis alone.
Team
CO-FOUNDER & SCIENTIFIC LEAD
Dr. Gil Shamai
Leads company activity, product development and clinical translation following a decade of research at the Technion.
CO-FOUNDER
Prof. Ron Kimmel
Head of the Geometric Image Processing Lab at the Technion and a serial MedTech entrepreneur.
Built with a global clinical network.
Collaborating with leading oncologists, pathologists, trial investigators and medical centers.
Work with us
Let’s improve the next treatment decision.
For clinical partnerships, data collaborations and investment inquiries.
Contact Phenotix